A basic research study using breast cancer cell lines was conducted as a non-clinical collaborative study between Mie University and Eisai Co., Ltd. Paclitaxel exhibited an increased 50% inhibitory concentration (IC50) in PIK3CA mutant cell lines compared with the PIK3CA wild-type cell line. This evidence concerns the gene PIK3CA and breast carcinoma.